Background: African American breast cancer patients have lower frequency of hormone receptor-positive (HR+)/human epidermal growth factor receptor 2 (HER2)-negative disease and higher subtype-specific mortality. Racial differences in molecular subtype within clinically defined subgroups are not well understood. Methods: Using data and biospecimens from the population-based Carolina Breast Cancer Study (CBCS) Phase 3 (2008-2013), we classified 980 invasive breast cancers using RNA expression-based PAM50 subtype and recurrence (ROR) score that reflects proliferation and tumor size. Molecular subtypes (Luminal A, Luminal B, HER2-enriched, and Basal-like) and ROR scores (high vs low/medium) were compared by race (blacks vs whites) and age (≤50 years vs > 50 years) using chi-square tests and analysis of variance tests. Results: Black women of all ages had a statistically significantly lower frequency of Luminal A breast cancer (25.4% and 33.6% in blacks vs 42.8% and 52.1% in whites; younger and older, respectively). All other subtype frequencies were higher in black women (case-only odds ratio [OR] = 3.11, 95% confidence interval [CI] = 2.22 to 4.37, for Basal-like; OR = 1.45, 95% CI = 1.02 to 2.06, for Luminal B; OR = 2.04, 95% CI = 1.33 to 3.13, for HER2-enriched). Among clinically HR+/HER2- cases, Luminal A subtype was less common and ROR scores were statistically significantly higher among black women. Conclusions: Multigene assays highlight racial disparities in tumor subtype distribution that persist even in clinically defined subgroups. Differences in tumor biology (eg, HER2-enriched status) may be targetable to reduce disparities among clinically ER+/HER2- cases.
Background: African American breast cancerpatients have lower frequency of hormone receptor-positive (HR+)/human epidermal growth factor receptor 2 (HER2)-negative disease and higher subtype-specific mortality. Racial differences in molecular subtype within clinically defined subgroups are not well understood. Methods: Using data and biospecimens from the population-based Carolina Breast Cancer Study (CBCS) Phase 3 (2008-2013), we classified 980 invasive breast cancers using RNA expression-based PAM50 subtype and recurrence (ROR) score that reflects proliferation and tumor size. Molecular subtypes (Luminal A, Luminal B, HER2-enriched, and Basal-like) and ROR scores (high vs low/medium) were compared by race (blacks vs whites) and age (≤50 years vs > 50 years) using chi-square tests and analysis of variance tests. Results: Black women of all ages had a statistically significantly lower frequency of Luminal A breast cancer (25.4% and 33.6% in blacks vs 42.8% and 52.1% in whites; younger and older, respectively). All other subtype frequencies were higher in black women (case-only odds ratio [OR] = 3.11, 95% confidence interval [CI] = 2.22 to 4.37, for Basal-like; OR = 1.45, 95% CI = 1.02 to 2.06, for Luminal B; OR = 2.04, 95% CI = 1.33 to 3.13, for HER2-enriched). Among clinically HR+/HER2- cases, Luminal A subtype was less common and ROR scores were statistically significantly higher among black women. Conclusions: Multigene assays highlight racial disparities in tumor subtype distribution that persist even in clinically defined subgroups. Differences in tumor biology (eg, HER2-enriched status) may be targetable to reduce disparities among clinically ER+/HER2- cases.
Authors: Monica D'Arcy; Jodie Fleming; Whitney R Robinson; Erin L Kirk; Charles M Perou; Melissa A Troester Journal: Breast Cancer Res Treat Date: 2015-06-25 Impact factor: 4.872
Authors: Erica T Warner; Rulla M Tamimi; Melissa E Hughes; Rebecca A Ottesen; Yu-Ning Wong; Stephen B Edge; Richard L Theriault; Douglas W Blayney; Joyce C Niland; Eric P Winer; Jane C Weeks; Ann H Partridge Journal: J Clin Oncol Date: 2015-05-11 Impact factor: 44.544
Authors: Lyndsay N Harris; Nofisat Ismaila; Lisa M McShane; Fabrice Andre; Deborah E Collyar; Ana M Gonzalez-Angulo; Elizabeth H Hammond; Nicole M Kuderer; Minetta C Liu; Robert G Mennel; Catherine Van Poznak; Robert C Bast; Daniel F Hayes Journal: J Clin Oncol Date: 2016-02-08 Impact factor: 44.544
Authors: Vanessa B Sheppard; Suzanne C O'Neill; Asma Dilawari; Sara Horton; Fikru A Hirpa; Claudine Isaacs Journal: Clin Breast Cancer Date: 2014-12-01 Impact factor: 3.225
Authors: Megan C Roberts; Morris Weinberger; Stacie B Dusetzina; Michaela A Dinan; Katherine E Reeder-Hayes; Lisa A Carey; Melissa A Troester; Stephanie B Wheeler Journal: J Clin Oncol Date: 2015-11-23 Impact factor: 44.544
Authors: Megan C Roberts; Morris Weinberger; Stacie B Dusetzina; Michaela A Dinan; Katherine E Reeder-Hayes; Melissa A Troester; Lisa A Carey; Stephanie B Wheeler Journal: Breast Cancer Res Treat Date: 2015-07-28 Impact factor: 4.872
Authors: Joel S Parker; Michael Mullins; Maggie C U Cheang; Samuel Leung; David Voduc; Tammi Vickery; Sherri Davies; Christiane Fauron; Xiaping He; Zhiyuan Hu; John F Quackenbush; Inge J Stijleman; Juan Palazzo; J S Marron; Andrew B Nobel; Elaine Mardis; Torsten O Nielsen; Matthew J Ellis; Charles M Perou; Philip S Bernard Journal: J Clin Oncol Date: 2009-02-09 Impact factor: 44.544
Authors: William F Anderson; Philip S Rosenberg; Idan Menashe; Aya Mitani; Ruth M Pfeiffer Journal: J Natl Cancer Inst Date: 2008-12-09 Impact factor: 13.506
Authors: S David Nathanson; David Krag; Henry M Kuerer; Lisa A Newman; Markus Brown; Dontscho Kerjaschki; Ethel R Pereira; Timothy P Padera Journal: Clin Exp Metastasis Date: 2018-05-23 Impact factor: 5.150
Authors: Brittny C Davis Lynn; Philip S Rosenberg; William F Anderson; Gretchen L Gierach Journal: J Natl Cancer Inst Date: 2018-11-01 Impact factor: 13.506
Authors: Jung S Byun; Sandeep K Singhal; Samson Park; Dae Ik Yi; Tingfen Yan; Ambar Caban; Alana Jones; Partha Mukhopadhyay; Sara M Gil; Stephen M Hewitt; Lisa Newman; Melissa B Davis; Brittany D Jenkins; Jorge L Sepulveda; Adriana De Siervi; Anna María Nápoles; Nasreen A Vohra; Kevin Gardner Journal: Clin Cancer Res Date: 2020-01-07 Impact factor: 12.531
Authors: Katherine E Reeder-Hayes; Sophie E Mayer; Andrew F Olshan; Stephanie B Wheeler; Lisa A Carey; Chiu-Kit Tse; Mary Elizabeth Bell; Melissa A Troester Journal: Cancer Date: 2019-08-09 Impact factor: 6.860
Authors: Halei C Benefield; Emily C Zabor; Yue Shan; Emma H Allott; Colin B Begg; Melissa A Troester Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-08-08 Impact factor: 4.254
Authors: Halei C Benefield; Emma H Allott; Katherine E Reeder-Hayes; Charles M Perou; Lisa A Carey; Joseph Geradts; Xuezheng Sun; Benjamin C Calhoun; Melissa A Troester Journal: J Natl Cancer Inst Date: 2020-07-01 Impact factor: 13.506
Authors: Yunan Han; Zhi-Feng Miao; Min Lian; Lindsay L Peterson; Graham A Colditz; Ying Liu Journal: Breast Cancer Res Treat Date: 2020-09-14 Impact factor: 4.872